Dumancić Jelena, Marković Asja Stipić
Department of Clinical Immunology, Pulmonology and Rheumatology, University Department of Internal Medicine, Sveti Duh University Hospital, Zagreb, Croatia.
Acta Med Croatica. 2012 May;66(2):111-4.
A large number of individuals experiencing anaphylactic reaction to neuromuscular blocking agents have not previously been in contact with them. The search for a substance inducing sensitization to muscle relaxants has led Norwegian and Swedish scientists to pholcodine, a cough suppressant, which is widely used in Europe and worldwide. Ammonium ion is an epitope common to pholcodine and neuromuscular blocking agents and it is the basis of their cross-reactivity. Based on the results of published studies that pointed to a connection of the use of pholcodine and perioperative anaphylactic reaction, pholcodine was withdrawn from the Norwegian market and subsequent research revealed a reduction of anaphylactic reactions in that country. In its latest report, the European Medicines Agency made a decision not to withdraw pholcodine mixtures from the market but it urged further research with the aim to clarify the cross-reactivity between pholcodine and neuromuscular blocking agents.
许多对神经肌肉阻滞剂发生过敏反应的人此前并未接触过此类药物。为寻找导致对肌肉松弛剂致敏的物质,挪威和瑞典科学家将目光投向了福尔可定,一种在欧洲及全球广泛使用的止咳药。铵离子是福尔可定和神经肌肉阻滞剂共有的表位,也是它们交叉反应的基础。基于已发表研究结果表明福尔可定的使用与围手术期过敏反应有关联,福尔可定已从挪威市场撤下,随后的研究显示该国过敏反应有所减少。欧洲药品管理局在其最新报告中决定不将含福尔可定的混合物从市场上撤下,但敦促开展进一步研究,以阐明福尔可定与神经肌肉阻滞剂之间的交叉反应。